Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients
- PMID: 18180912
- DOI: 10.1007/s00228-007-0443-9
Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients
Abstract
Background: The marketing of sumatriptan, a selective serotonin (5-HT) 1B/1D agonist, first of the class of triptans, has increased the therapeutic options for the treatment of migraine attacks. However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan.
Objective: To evaluate whether the interindividual differences in the clinical response following oral administration of sumatriptan are due to differences in its pharmacokinetics.
Methods: We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatriptan. Patients were studied during headache-free intervals. Blood samples were taken serially from baseline to 360 min after oral administration and from baseline to 180 min after subcutaneous injection. Sumatriptan plasma concentrations were determined by high-performance liquid chromatography (HPLC) with an electrochemical detector.
Results: Following oral dosing, patients of group A absorbed sumatriptan significantly faster and achieved early plasma levels significantly higher than patients of group B. The systemic exposure to sumatriptan during the first 2 h, which are the most important for rapid onset of action and for antimigraine efficacy, was significantly greater in group A than in group B (P < 0.001, Student's t test for independent data). On the other hand, after subcutaneous injection of sumatriptan, the profile of the curves was similar in all patients, and there were no differences in pharmacokinetics between group A and group B.
Conclusion: The slow rate and low extent of absorption of the drug during the first 2 h after dosing observed in patients of group B could explain their unsatisfactory response to oral sumatriptan.
Similar articles
-
Sumatriptan. An updated review of its use in migraine.Drugs. 1998 Jun;55(6):889-922. doi: 10.2165/00003495-199855060-00020. Drugs. 1998. PMID: 9617601 Review.
-
Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.J Pharmacokinet Biopharm. 1999 Apr;27(2):149-71. doi: 10.1023/a:1020601906027. J Pharmacokinet Biopharm. 1999. PMID: 10567953 Clinical Trial.
-
Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.Drugs. 2000 Dec;60(6):1259-87. doi: 10.2165/00003495-200060060-00003. Drugs. 2000. PMID: 11152011 Review.
-
Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.Clin Ther. 2010 Jun;32(6):1165-77. doi: 10.1016/j.clinthera.2010.06.014. Clin Ther. 2010. PMID: 20637969 Clinical Trial.
-
Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.Eur J Pharm Sci. 1998 Apr;6(2):99-104. doi: 10.1016/s0928-0987(97)00073-0. Eur J Pharm Sci. 1998. PMID: 9795022 Clinical Trial.
Cited by
-
Triptans: where things stand.Curr Treat Options Neurol. 2010 Sep;12(5):454-63. doi: 10.1007/s11940-010-0082-9. Curr Treat Options Neurol. 2010. PMID: 20842600
-
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.J Headache Pain. 2014 Dec 8;15(1):85. doi: 10.1186/1129-2377-15-85. J Headache Pain. 2014. PMID: 25488888 Free PMC article. Clinical Trial.
-
Polypharmacy Among Headache Patients: A Cross-Sectional Study.CNS Drugs. 2018 Jun;32(6):567-578. doi: 10.1007/s40263-018-0522-8. CNS Drugs. 2018. PMID: 29752625 Free PMC article.
-
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure.J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z. J Headache Pain. 2022. PMID: 36224519 Free PMC article. Review.
-
Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.J Headache Pain. 2011 Feb;12(1):5-12. doi: 10.1007/s10194-010-0258-4. Epub 2010 Sep 29. J Headache Pain. 2011. PMID: 20878535 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources